Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Press/Media
Datasets
Activities
Fellowships, Honors, and Prizes
Search by expertise, name or affiliation
Formoterol fumarate inhalation solution (Perforomist™) for COPD
Jeffrey B. Rubins
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Formoterol fumarate inhalation solution (Perforomist™) for COPD'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chronic Obstructive Pulmonary Disease
100%
Inhalation
100%
Perforomist
100%
Formoterol Fumarate
100%
Bronchodilation
75%
Hyperinflation
50%
Formoterol
50%
Effective Treatment
25%
Twice Daily
25%
Forced Expiratory Volume in 1 Second (FEV1)
25%
Dry Powder Inhaler
25%
Rapid Onset
25%
Airway Obstruction
25%
Tiotropium
25%
Chronic Obstructive Pulmonary Disease Patient
25%
Long-acting Anticholinergic
25%
Rescue Therapy
25%
Cumulative Effects
25%
Rescue Treatment
25%
Metered Dose
25%
Short-acting Bronchodilators
25%
Nebulized Therapy
25%
Anticholinergic Bronchodilators
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Formoterol Fumarate
100%
Cholinergic Receptor Blocking Agent
33%
Bronchodilating Agent
33%
Formoterol
33%
Airway Obstruction
16%
Nebulizer
16%
Dry Powder Inhaler
16%